New Cell Therapy for Recurring Brain Cancer
Part of Cancer clinical trials.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your brain cancer must be confirmed by a biopsy and be WHO Grade 4 astrocytoma
- Your cancer has come back or is growing (confirmed by MRI) and surgery is possible
- You completed standard treatment: surgery, radiation, and chemotherapy (temozolomide)
- You are between 18 and 75 years old and able to handle the physical demands of treatment
- You can have MRI scans with contrast dye and stay in the Twin Cities area during treatment
- Your organs are working well enough for this treatment, and you are not pregnant or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
Hear when a new Astrocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.